105 completed, 13 unknown, 5 terminated, 5 withdrawn. 46 Phase 3, 35 Phase 2, 29 Phase 4, 9 Not applicable, 7 Phase 1.
Follow Allergic Conjunctivitis: new trials by email Literature Review of Allergic Conjunctivitis trials Research Report on Allergic Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy REGN-2Cat, Freneslerbart, Mevonlerbart - Allergic Conjunctivitis | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 570 | 2026-07-31 | 2026-11-05 |
| Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy REGN5713, REGN5715, Placebo - Allergic Conjunctivitis | Phase 3 | Terminated | Regeneron Pharmaceuticals | 24 | 2026-01-10 | 2026-09-01 |
| Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects Allergic Rhinitis, Allergic Conjunctivitis | Not yet recruiting | Sven Schneider, MD | 152 | 2025-12-01 | 2025-05-07 | |
| Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis TL-925, Placebo - Allergic Conjunctivitis | Phase 2 | Recruiting | Telios Pharma, Inc. | 60 | 2025-10-23 | 2025-11-25 |
| A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy REGN5713, REGN5715, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Regeneron Pharmaceuticals | 54 | 2024-11-19 | 2026-04-21 |
| A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy REGN1908, REGN1909, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Regeneron Pharmaceuticals | 64 | 2024-11-06 | 2026-05-08 |
| Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis TL-925, Placebo - Allergic Conjunctivitis | Phase 2 | Recruiting | Telios Pharma, Inc. | 66 | 2024-10-03 | 2024-11-13 |
| A Study Of TL-925 For The Treatment of AC TL-925, Placebo - Allergic Conjunctivitis | Phase 2 | Completed | Telios Pharma, Inc. | 80 | 2024-04-11 | 2024-07-03 |
| A Study of TL-925 for the Treatment of Allergic Conjunctivitis TL-925, Placebo - Allergic Conjunctivitis | Phase 2 | Unknown | Telios Pharma, Inc. | 70 | 2023-11-01 | 2023-12-01 |
| A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults MDI-1228_mesylate Ophthalmic Solution, Placebo - Allergic Conjunctivitis | Phase 1 | Completed | Shanghai Medinno Pharmaceutical Technology Co., Ltd. | 40 | 2023-10-06 | 2024-07-09 |
| Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction NAAGA (N-acetyl-aspartyl-glutamate) 49 mg/mL, azelastine hydrochloride 0.05% - Allergic Conjunctivitis, Dry Eye Disease (DED) | Phase 4 | Completed | Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona | 134 | 2023-04-21 | 2025-07-15 |
| Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 512 | 2023-04-20 | 2025-07-10 |
| PMCF Study to Evaluate Performance and Safety of "Xanoftal Next" HPMC-HA eyedrops - Allergic Conjunctivitis, Dry Eye | Not applicable | Completed | C.O.C. Farmaceutici S.r.l. | 20 | 2022-12-02 | 2023-05-06 |
| Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035% - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 188 | 2022-10-12 | 2025-02-14 |
| The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic Conjunctivitis Vitamin D, Placebo - Allergic Conjunctivitis | Not applicable | Unknown | China Medical University Hospital | 150 | 2022-08-08 | 2024-07-03 |
| PMCF Study to Evaluate Performance and Safety of "Optrex Double Action Soothing and Lubricating Drops" Eye drops for itchy and water eyes - Allergic Conjunctivitis, Dry Eye | Not applicable | Completed | C.O.C. Farmaceutici S.r.l. | 20 | 2022-06-07 | 2023-05-06 |
| The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 131 | 2022-01-21 | 2026-05-14 |
| A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis olopatadine hydrochloride ophthalmic solution 0.7%), Fluticasone Propionate, Tears Naturale - Allergic Conjunctivitis | Phase 4 | Completed | Andover Research Eye Institute | 61 | 2021-12-31 | 2022-09-02 |
| A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis olopatadine hydrochloride ophthalmic solution 0.7%, loratadine 10 mg, Tears Naturale - Allergic Conjunctivitis | Phase 4 | Completed | Andover Research Eye Institute | 58 | 2021-12-14 | 2022-05-03 |
| Airway Immune Response to Allergens (Use Lay Language Here) Segmental allergen challenge - Allergic Asthma, Allergy to Cats | Phase 1 | Unknown | JOSALYN CHO | 12 | 2021-10-28 | 2023-08-31 |
Showing 20 of 134. Sign in to see all of them.
Conjunctivitis, Allergic (134) · Rhinitis, Allergic (18) · Hypersensitivity (15) · Conjunctivitis (10) · Rhinitis, Allergic, Seasonal (8) · Asthma (7) · Dry Eye Syndromes (5) · Dermatitis, Atopic (4) · Food Hypersensitivity (3) · Lacerations (2) · Dust Mite Allergy (1) · Keratoconjunctivitis, Infectious (1) · Milk Hypersensitivity (1) · Nasal Obstruction (1) · Paresthesia (1)
Conjunctival Diseases (134) · Eye Diseases (134) · Hypersensitivity, Immediate (134) · Immune System Diseases (134) · Conjunctivitis (124) · Hypersensitivity (119) · Nose Diseases (23) · Otorhinolaryngologic Diseases (23) · Respiratory Hypersensitivity (23) · Respiratory Tract Diseases (23) · Rhinitis (23) · Bronchial Diseases (7) · Lung Diseases (7) · Lung Diseases, Obstructive (7) · Skin Diseases (7)
Olopatadine Hydrochloride (23) · Ketotifen (8) · Ophthalmic Solutions (7) · bepotastine besilate (6) · Dexamethasone (5) · Lubricant Eye Drops (4) · alcaftadine (4) · Methylprednisolone (3) · Naphazoline (3) · Brimonidine Tartrate (2) · Fluticasone (2) · Loteprednol Etabonate (2) · bilastine (2) · epinastine (2) · ketotifen fumarate ophthalmic solution (2)
Alcon Research (21) · Bausch & Lomb Incorporated (12) · Vistakon Pharmaceuticals (8) · ORA, Inc. (6) · Aciex Therapeutics, Inc. (5) · Aldeyra Therapeutics, Inc. (5) · Faes Farma, S.A. (4) · Regeneron Pharmaceuticals (4) · Telios Pharma, Inc. (4) · Hom, Milton M., OD, FAAO (3) · Allergy Therapeutics (2) · Andover Research Eye Institute (2) · C.O.C. Farmaceutici S.r.l. (2) · Fovea Pharmaceuticals SA (2) · Marinomed Biotech AG (2)
United States (74) · Canada (8) · Japan (6) · Italy (5) · Germany (4) · Austria (3) · Finland (3) · South Korea (3) · France (2) · Israel (2) · Argentina (1) · Australia (1) · China (1) · Czechia (1) · Denmark (1)
Brian Pall, OD, MS, FAAO (4) · Abhijit Narvekar, MS, MBBS (3) · Gail L Torkildsen, MD (3) · Tim McNamara, PharmD (3) · Edward Meier, MD (2) · Gail Torkildsen, MD (2) · Ingerman Avner, MD (2) · Milton M Hom, OD FAAO (2) · Stacey Ackerman, MD (2) · Tarek Shazly, MD (2) · Tuyen Ong, MD (2) · Ahmad M Fahmy, O.D. (1) · Alessandra Cesano, MD (1)
PMID 27466061, PMID 16877412, PMID 17021840, PMID 18595980, PMID 19127072, PMID 20488431, PMID 21250860, PMID 21771118, PMID 22093109, PMID 22991696, PMID 23484763, PMID 24517417, PMID 25104279, PMID 25163405, PMID 26266427, PMID 28007090, PMID 30326954, PMID 30472801, PMID 32407947, PMID 34857814, PMID 35585427, PMID 36811846, PMID 37438187, PMID 38105911, PMID 38687061, PMID 39328900, PMID 39386177
2016 (1), 2018 (1), 2019 (1), R01EY012526 (1)